Leukoreduction Filters in Transfusion Medicine: 4 Factors That Matter Most
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, has shared a post on LinkedIn:
”Do all leukoreduction filters perform the same? Not really…
In transfusion medicine, not all filters are equal. Behind what looks like a simple device lie technical choices that directly impact patient safety and blood product quality. So… how do you know which one is the right filter?
Here are the 4 key criteria:
Leukoreduction performance
• European standard: ≤ 1 million residual white blood cells
• AABB standard: ≤ 5 million
In practice, users often expect a filter to perform 5 to 10 times better than these limits, to ensure stability and safety.
Residual losses
An efficient filter retains leukocytes… but it may also trap red blood cells. Too much loss = a direct impact on hemoglobin levels, or on the required minimum recovery (≥ 85% according to AABB). The challenge is to find the right balance.
Filtration speed
Some centers want ultra-fast processing. Others prefer quality over speed. It all depends on the number of units to process daily and the available “masked time.”
Final component quality
Filters also influence hemolysis in red blood cells or platelet activation in PC. An invisible variable… but one that determines therapeutic value.
Conclusion – there is no such thing as a “perfect” filter. The right filter is the one that fits your process, your priorities, and your patients.
And you, which of these criteria weighs the most in your decisions?”
Stay updated on the emerging in transfusion medicine with Hemostasis Today.
-
Jan 29, 2026, 14:02Emma Lefrancais on Alarmin IL33 and Platelet Biology
-
Jan 29, 2026, 13:44Sia A: One of My Favorite Conversations from ASH
-
Jan 29, 2026, 13:34Sarah Matuja on Tanzania Stroke Project
-
Jan 29, 2026, 13:28Nancy Di Salvo on Amplifying Rare Disease Voices Through Partnership
-
Jan 29, 2026, 13:21Raul Santos Shares The Results of ORION-16: On The Efficacy and Safety of Inclisiran
-
Jan 29, 2026, 05:22Aravind Palraj Draws a Comparison Between APS and Lupus Cerebritis
-
Jan 29, 2026, 05:09Edina Cenko on Expanding Cardiovascular Risk: From Ischaemia to Emerging Frontiers
-
Jan 29, 2026, 04:58Anna Randi Shares the Latest Episode of The VWF and Angiogenesis Story from Her Lab
-
Jan 29, 2026, 04:49Ruah Alyamany on Her Contribution to Establishing The Role of IgM in APS